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Abstract
Background: Preclinical research indicate that vascular disrupting agent (VDA) treatment induces extensive tumor
death but also a systemic mobilization of bone marrow derived cells including endothelial progenitor cells (EPC)
leading to revascularization and renewed growth within the residual tumor. This study investigates if combination
of VDA with the anti-angiogenic agent Sunitinib increases the treatment efficacy in a colorectal liver metastases
mouse model.
Methods: CBA mice with established liver metastases were given a single dose of OXi4503 at day 16 post tumor
induction, a daily dose of Sunitinib starting at day 14 or day 16 post tumor induction or a combination of Sunitinib
given daily from day 14 or day 16 post tumor induction in combination with a single dose of OXi4503 at day 16.
Treatment was terminated at day 21 post tumor induction and its effects were assessed using stereological and
immunohistochemical techniques. Long term effects were assessed in a survival study.
Results: Combination with long (7 day) Sunitinib treatment lead to liver toxicity but this was ameliorated in the
shorter (5 day) treatment without significantly altering the effects on tumor reduction. Combination treatment
resulted in significant reduction of viable tumor, reduction in tumor vasculature, reduction in tumor proliferation,
increase in tumor apoptosis and prolonged mouse survival compared to control and single arm treatments.
Complete tumor eradication was not achieved. Redistribution of E-cadherin and strong up regulation of ZEB1
and Vimentin were observed in the surviving tumor; indicative of epithelial to mesenchymal transition (EMT),
a mechanism that could contribute to tumor resistance.
Conclusions: Combination treatment significantly reduces viable tumor and prolongs animal survival. EMT in
the surviving tumor may prevent total tumor eradication and could provide novel targets for a more lasting treatment.
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Background
Tumor vasculature is essential for the growth and devel-
opment of tumors beyond 1–2 mm3 [1, 2]. Unlike host
vessels, tumor vessels are immature, unstable, leaky and
deficient in pericyte and smooth muscle coverage. They
undergo constant remodelling in order to supply the
rapidly growing tumor with oxygen and nutrients [3].
These fundamental differences in tumor vessels com-
pared to host vessels make them more sensitive to the
effects of VDAs [4]. OXi4503 is a potent VDA which
has demonstrated immediate vascular shutdown leading
to ischemia and tumor necrosis [5–7]. Despite extensive
tumor necrosis however OXi4503 does not completely
eradicate the tumor. Incomplete destruction of the
tumor is evident by the presence of a distinctive rim of
viable tumor cells at the tumor periphery [5, 6]. These
surviving tumor cells undergo vigorous revascularization
through angiogenesis resulting in disease recurrence.
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Previous studies including ours have implicated tumor
revascularization as a major contributor to residual
disease. Combination treatments of VDAs with anti-
angiogenic agents (AAs) have the potential to inhibit
re-vascularization of the residual tumor and thus enhance
the efficacy of the treatment [8]. Anti-angiogenic agents
unlike VDAs prevent the formation of new blood vessels.
Monoclonal antibodies to VEGF (Avastin®) and a number
of small tyrosine kinase inhibitors targeting multiple re-
ceptors involved in angiogenesis including the VEGF re-
ceptors have been approved for clinical use. Our previous
findings, together with other preclinical data support the
rationale of combining VDAs with AAs as a complemen-
tary treatment strategy [9–12]. In the current study we
evaluate the antitumor efficacy of combining OXi4503
with the anti-angiogenic agent, Sunitinib, in a colorectal
liver metastasis (CRLM) mouse model. Sunitinib a multi-
targeting inhibitor of the receptor tyrosine kinases (RTK)
of VEGFR-1/-2/-3, PDGFR-α/-β, FLT3, stem cell growth
factor receptor KIT and RET [13] has been approved for
the treatment of advanced renal cell carcinoma, imatinib
resistant or imatinib-intolerant gastrointestinal stromal tu-
mors, and unresectable or metastatic well differentiated
pancreatic neuroendocrine tumors [14–18].
Methods
Animals and experimental model of colorectal liver
metastasis
The CRLM model used in this study was developed and
fully characterized in our laboratory. The tumor grows
orthotopically in a fully immunocompetent host with
growth characteristics similar to human metastasis [19].
Male CBA mice (Laboratory Animal services, University
of Adelaide, South Australia) were maintained in standard
cages with irradiated food and water supplied ad libitum.
The primary cancer cell tumor MoCR was derived from a
dimethyl hydrazine (DMH)-induced primary colon carcin-
oma in the CBA mouse and maintained in vivo by serial
passage in the flanks of CBA mice. For passage and ex-
perimentation, subcutaneous tumors were teased apart,
passed through a filter, treated with EDTA and washed in
PBS to make a single cell suspension. Liver metastases
were induced by intrasplenic injection of 5 × 104 tumor
cells followed by splenectomy. Metastases are fully estab-
lished by 21 days following tumor induction [19]. All ani-
mal studies were approved and conducted under the
supervision and in accordance with the guidelines set by
the Austin Hospital animal ethics committee.
Drugs and treatment protocol
Treatment was administered 16 days after induction of
liver metastases when tumors are well established.
OXi4503 (Combretastatin A-1 trans-stilbene), kindly do-
nated by OXiGENE (OXiGENE Inc. South San Francisco,
CA), was freshly prepared by dissolving in 0.9 % sterile sa-
line (NaCl) and protected from light. A single maximum
tolerated dose of OXi4503, determined previously to be
100 mg/kg was administered via intraperitoneal injection
[6]. Sunitinib malate (LC Laboratories, Boston, USA) was
freshly dissolved in sterile saline and administered in daily
intraperitoneal injections of 40 mg/kg as reported in other
studies [20].
Three different studies were performed. In the first
study animals with colorectal liver metastases were
divided into four groups; The OXi4503 treated group re-
ceived a single dose of 100 mg/kg of OXi4503 intraperi-
tonealy at day 16 post tumor induction. The Sunitinib
treated group received intraperitoneal daily doses of
40 mg/kg of Sunitinib malate from day 14 to 21 post
tumor induction. The combination group received
40 mg/kg of Sunitinib daily from day 14 to 21 post
tumor induction and additionally received a single dose
of 100 mg/kg of OXi4503 at day 16 post tumor induc-
tion. The control group received daily intraperitoneal
saline injections from day 14 to 21. In the second and
third studies Sunitinib treatment for the single and com-
bination arms of the study started at day 16. All other
conditions were as for the first study. Tissues were col-
lected 21 days post tumor induction in the first and
second studies. The third was a survival study and once
treatment was terminated at day 21 mice were moni-
tored for health indicators and were killed when these
became significant.
Stereology
At the endpoint laparotomy was performed and the ab-
dominal cavity examined for indications of macroscopic
extra- hepatic metastases; paying close attention to the
splenic bed. The liver was carefully excised and har-
vested. Immediately following excision liver weights
were recorded. Organs were then fixed in formalin
(10 %) (Sigma Aldrich, Castle Hill, NSW, Australia) for
24 h and then transferred to 70 % ethanol. Images of the
whole liver were taken to examine the tumor distribution
and burden load. The liver was then transversely sliced
into sections of 1.5 mm thickness using a tissue fraction-
ator. For large livers (Saline control and OXi4503 treated)
every second slice was sampled for analysis. For smaller
livers (Sunitinib and Sunitinib/OXi4503 treated tumors)
every slice was taken for analysis due to small number of
sections. Liver slices were placed on a clear plastic plate; a
digital camera (Nikon Coolpix5000, E500) was used to
capture the images and these were analysed using image
analysis software (Image Pro Plus, Perth, Australia).
Tumors were visualised as distinctive white/cream
coloured areas against the red/brown liver tissue. Each
tumor outline was traced using image analysis software to
determine the area occupied by the tumor. This stereology
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technique was used to determine the number of tumor nod-
ules, tumor volume and the percentage of liver metastases.
Immunohistochemistry
Formalin fixed paraffin tissue sections (4 μm) were used
with an indirect peroxidase labeling technique (Envision
Plus, DAKO, Australia). Following deparaffinization and
rehydration, endogenous peroxidase activity was blocked
with 3 % H2O2 and non-specific binding inhibited with
10 % normal goat serum (01–6201 Zymed Laboratories,
USA). Heat induced epitope retrieval was used. Antigens
were visualised by immunohistochemical staining using
their respective antibodies diluted as follows: (CD34
1:500, AbD serotec MCA18256; Ki-67 1:100, Thermo-
scientific, RM-9106-S1; caspase 3 1:800, R&D AF835)
and EMT markers (ZEB1 1:200, Santa Cruz sc-25388;
Vimentin 1:300, Santa Cruz sc-5565; E-cadherin 1:500
Sana Cruz sc-7870; b-catenin 1:300, Santa Cruz sc-7199)
Negative controls were stained by the corresponding iso-
type antibodies. Following primary antibody treatment,
sections were incubated with a horseradish peroxidase
labelled polymer secondary antibody. The antigen-
antibody complex was visualized by diaminobenzene
(DAB) Peroxidase Substrate Solution (DAKO, Australia).
Each treatment group consisted of 5–8 animals. A mini-
mum of ten tumors were assessed for each treatment
group and from 3 to 15 images per tumor, depending on
tumor size, were captured for analysis.
Statistical analysis
All data was represented as the mean ± standard error of
the mean. Statistical analysis was conducted using SPSS
(Statistical Package for the Social Sciences,™ version 10,
Chicago, Illinois, USA) using both parametric and non-
parametric analytical tests as appropriate. All statistical
tests were two-sided and a P value of 0.05 was consid-
ered statistically significant.
Results
Combination therapy has an additive effect on tumor death
A single OXi4503 treatment has profound effects imme-
diately following treatment and it peaks by 24 h, then
there is a robust re-vascularization and regrowth by day
5 post-treatment [10] and Additional file 1. In contrast
continuous treatment with Sunitinib reduces the tumor
mass gradually (Additional file 1).
Visual examination of the livers collected at the
endpoint (day 21) indicate all treatment modalities
have significantly less tumor burden than the control,
especially the Sunitinib and combination treatments
(Fig. 1a, top panel). Livers in the combination treated
group have a yellow tinge suggesting liver damage
(Fig. 1a, top panel). Liver weight is commonly used as
an indication of tumor burden. For all treatment
regimens liver weight was significantly lower than the
untreated controls (P < 0.05) indicating tumor death
and/or inhibition of tumor proliferation (Fig. 1a, lower
panel). However there was no significant difference be-
tween the liver weights of the Sunitinib treatment and the
OXi4503/Sunitinib combination (Fig. 1a, lower panel).
Furthermore, Sunitinib/OXi4503 combination treated
livers and Sunitinib treated livers demonstrated a signifi-
cantly decreased mean liver weight compared to livers
from non tumor bearing animals (Fig. 1a, lower panel)
(P = 0.007 and P = 0.011, respectively), again suggesting
some degree of liver toxicity. Histological examination
of the tumors demonstrate less live tumor remaining
after the combination treatment than in either of the
single arm treatments (Fig. 1b-d). In the combination
treatment small patches of viable tumor are seen only
in the periphery most often not forming a continuous
live rim (Fig. 1b). Quantitation of live tumor area dem-
onstrate significantly less live tumor in the combination
treatment compared to single arm treatments and
about half the live tumor area compared to Sunitinib
(P < 0.01, Fig. 1c). Additionally the density of viable
tumor cells in the combination treatment is less than in
the single arm treatments and often only detached sin-
gle viable cells can be seen, (arrows, Fig. 1d) indicating
that the combination effect on tumour is more exten-
sive than the area enumeration shows. These results in-
dicate that measurement of viable tumor is a better
indication of treatment efficacy. Further histological
examination of the tissues confirms liver damage in the
combination treatment as suggested from the visual
liver appearance and the reduced liver weight. Extensive
areas of liver tissue adjacent to tumor nodules (arrows
in Fig. 1b and d) show loss of the classical sinusoidal
architecture and cells display loss of nuclei and visible
cell boundaries. Some areas of liver tissue distant to the
tumor also display damage (not shown). Histological
examination of the Sunitinib only treatment displayed lim-
ited liver damage in only two of the animals (not shown).
OXi4503 combination with shorter Sunitinib treatment
confers enhanced efficacy with no apparent liver toxicity
In view of the observed liver toxicity, in the second
study Sunitinib was administered on day 16 post tumor
induction, the same time as OXi4503. Visual examin-
ation of the liver did not demonstrate the yellow colour-
ing seen in the combination treatment when Sunitinib
treatment commenced on day 14 (Fig. 2a) Livers weights
from the combination treatment commencing on day 16
were not significantly different to non-tumor bearing
livers (Fig. 2b) unlike the results in the first study. Fur-
thermore upon histological examination no liver damage
was observed in this group with liver tissue immediate
and distal to the tumor remaining morphologically
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unchanged with large nuclei and the classical sinusoid
architecture intact (Fig. 2c). The effectiveness of starting
Sunitinib treatment on day 16 post tumor induction
compared to day 14 post tumor induction was measured
by calculating the percentage of viable rim following
treatment. Quantitation of the percentage of viable rim
following the two different treatment regimens revealed
an increasing trend for reduced efficacy in the shorter
treatment but did not reach significance (P = 0.105, re-
sult not shown). The results suggest liver cytotoxicity in
the combination treatment could be limited by changing
the treatment schedule while still maintaining increased
efficacy compared to single arm treatments.
OXi4503/Sunitinib combination treatment exerts
anti-angiogenic effects on tumors
By day five after treatment (endpoint in this study) vig-
orous revascularization occurs in the residual tumor in
the OXi4503 treated animals (P < 0.001) compared to
control, (Fig. 3). Interestingly the original vessels in the
necrotic centre appear to be repopulating with CD34
staining endothelial cells, despite absence of viable
tumor in that area (Fig. 3 OXi4503 second inset). In
contrast in the Sunitinib treatment and especially in the
combination treatment, tumor vessels are significantly
reduced at this endpoint compared to untreated control
and OXi4503 treated groups (P < 0.001) (Fig. 3). In the
Fig. 1 Treatment effects on CRC liver metastases. Sunitinib (40 mg/kg) was given daily from day 14 post tumor induction while OXi4503 (100 mg/kg)
was given as a single dose at day 16. a Livers with tumor metastases (upper panel). Liver weights (lower panel) expressed as mean value ± SEM, with
n ≥ 5 for each group. Significant decrease in liver weight in treatment groups compared to control (*P < 0.05). Significant decrease in liver weight in
Sunitinib and combination treatments compared to naïve liver group (#P < 0.011 and 0.007, respectively). Statistical significance determined using
ANOVA with post-hoc Tukey-HSD tests. b H&E staining tumor/liver tissues following treatment. Scale bar = 200 μm T = Tumor, L = Liver. Live tumor
areas enclosed within blue lines. Arrows in combination panel indicate areas of liver damage. c quantitation of live tumor area expressed
as mean value ± SEM, with n ≥ 5 for each group. (*P < 0.01 for combination vs control or other treatments). d magnification of inset in
combination panel (b) depicting low frequency of viable tumor cells (black arrows) and liver damage (yellow arrows). Scale bar = 50 μm
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Sunitinib treated group, major vessels are seen mainly in
the tumor host interface but a few major vessels persist
in central tumor regions (Fig. 3, Sunitinib, arrow). Add-
itionally there is a marked reduction in smaller vessels
within the viable tumor areas (Fig. 3). In the combin-
ation treatment vessels are only visible at the tumor
edge, being most likely host vessels (Fig. 3). These re-
sults demonstrate that in the combination group Suniti-
nib prevents the accelerated revascularization of the
residual tumor seen following a single dose of OXi4503
treatment. In addition significantly fewer tumor vessels
are seen in the combination treatment compared to sin-
gle arm Sunitinib treatment (P = 0.001).
Combination treatment reduces live tumor load by
inhibiting proliferation and increasing apoptosis
To determine the mechanisms of anti-tumorigenic ef-
fects of the different treatments we examined tumor
proliferation and apoptosis. Staining and quantitation of
Ki67 (Fig. 4a) revealed proliferation within the viable
Fig. 2 Shorter Sunitinib treatment ameliorates liver toxicity. Sunitinib (40 mg/kg) was given daily from either day 14 or day 16 post tumor induction.
OXi4503 (100 mg/kg) was given as a single dose at day 16. a Livers with tumor metastases (No yellow tinge in Day 16 combination treatment). b Liver
weight of treated vs control (#P < 0.05). Significant decrease in liver weight of Day 14 combination treatment vs naïve (non tumor bearing)
liver (*P < 0.011) but not in Day16. Data is expressed as mean value ± SEM, with n ≥ 5 for each group. Statistical significance determined using
ANOVA with post-hoc Tukey-HSD tests. c H&E staining tumor/liver tissues following treatment. L = liver, T = tumor. First column Scale bar = 200 μm
Second and third column images represent insets from first column images depicting liver damage (arrows) in liver tissue adjacent and
distant to tumors in Day 14 but not in Day 16 combination treatment. Scale bar = 50 μm
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tumor areas in all groups. While live tumor areas were sig-
nificantly larger in the controls and the regrowing
OXi4503 group, proliferation in the OXi4503 and the
Sunitinib treated groups is trending higher compared
to control but not reaching significance for either
treatment (Fig. 4b). In contrast the combination treat-
ment is trending lower compared to untreated control
and was significantly lower than either of single arm treat-
ments (P < 0.003, combination vs OXi4503 and P < 0.016,
combination vs Sunitinib) suggesting that reduced prolif-
eration or at least prevention of the proliferation stimula-
tion seen in each of the single arm treatments is one of
the mechanisms for the improved efficacy in the combin-
ation treatment. Staining with Caspase 3, a marker for ac-
tive apoptosis, showed increased cell apoptosis within the
viable tumor regions in all treatment groups and especially
in the Sunitinib and combination groups (Fig. 5a).
Apoptosis was not uniform but appeared in patches
within the viable tumor regions. Enumeration of caspase
positive cells (Fig. 5b) confirmed significant increase in
apoptosis (treatments vs control P < 0.003) In addition sig-
nificantly higher apoptosis occurred in the combination
group compared to the OXi4503 treatment, P < 0.006 and
the Sunitinib treatment, P < 0.02.
OXi4503/Sunitinib combination treatment of liver
metastases increases survival
A survival study was undertaken to test if the enhanced
tumor reduction seen in the combination treatment trans-
lates into survival advantage. Sunitinib/OXi4503 combin-
ation treatment significantly prolonged survival in tumor
bearing mice compared to saline treated control, OXi4503
and Sunitinib monotherapies. Sunitinib/OXi4503 treat-
ment Cumulative survival using the Kaplan–Meier ana-
lysis and a log rank test, demonstrate a significant
difference in survival between the Sunitinib/OXi4503
combination treatment and all other treatments (Fig. 6,
OXi4503/Sunitinib vs Control P < 0.004, vs OXi4503
P < 0.006, vs Sunitinib P < 0.005).
Morphological changes in residual tumor cells following
single and combination treatments show EMT
While the OXi4503/Sunitinib combination was more ef-
ficacious that either single arm treatment, complete
tumor eradication was not achieved. We investigated
whether cells surviving the treatment become resistant
by changing their morphology from epithelial to mesen-
chymal (Fig. 7 and Additional files 2 and 3). Untreated
tumors express high levels of E-cadherin localised
Fig. 3 Differences in blood vessel density following different treatment regimens. a Formalin fixed liver sections with CRC liver metastases were
stained with antibodies to CD34 (staining of endothelial cells). First column Scale bar = 200 μm. Second column depicts magnified inset regions
of first column images. Scale bar = 50 μm. T = live tumor, NT = necrotic tumor. Second inset in the OXi4503 treatment indicates central tumor vessels
recovering ahead of live tumor repopulation. Arrow in the Sunitinib treatment indicates intact central vessel surrounded with live tumor cells. Arrows in
the combination treatment show liver damage. b Quantification of CD34 positive vessels. Data is expressed as mean value ± SEM, with n ≥ 5 for each
group. Data was not normally distributed and non-parametric analysis was performed and statistical significance determined using Mann-Whitney U
test. (OXi4503 vs control *P < 0.001, Sunitinib and combination vs control *P < 0.001 and Sunitinib vs combination #P = 0.001)
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mainly in the cell junctions and exhibit the characteristic
cobblestone staining of epithelial cells (Fig. 7 control).
ZEB1 is expressed strongly by infiltrating stroma cells
that are found scattered throughout the tumor and most
frequently closer to the tumor periphery and the adjacent
liver tissue. Vimentin is expressed at very low levels in the
control tumors but some infiltrating stroma cells stain
positive (Fig. 7 and Additional file 2, control). In our previ-
ous studies we found almost complete loss of E-cadherin
within an hour of OXi4503 treatment and significant up
regulation of ZEB1 and Vimentin [9]. At day five post
treatment (endpoint in this study) E-cadherin is expressed
at significantly lower levels compared to control, ZEB1 is
expressed at control levels, while Vimentin is significantly
higher than the control (Fig. 7, OXi4503 treated) as we
found in our previous study [9]. Interestingly in the
Sunitinib and the combination treatments at day five
post treatment while overall E-cadherin staining is
lower than the control there is a re-distribution from
the cell junctions to the cytoplasm and nucleus of live
tumor cells (Fig. 7, Sunitinib and combination treated).
ZEB1 expression in the Sunitinib and combination
treatments is significantly higher than in the control
tumors and displays mainly cytoplasmic localization.
The levels of Vimentin are also high in the Sunitinib
and combination treatments at day 5 (Fig. 7, Sunitinib
and combination treated). Additional file 3 depicts a
semi-quantitive enumeration of these results. The re-
sults show that ZEB1 expression remains high while the
treating agent is present as in the continuous treat-
ments of Sunitinib and the combination while in the
single OXi4503 treatment where the agent has been
eliminated by day 5, its levels returned to background.
Taken together, these results suggest that the tumor
cells which survive treatment undergo EMT which lasts
while the treating agent is present.
Discussion
VDA agents like OXi4503 destroy the established tumor
vasculature resulting in very significant tumor death
[21], however the treatment also induces a robust influx
of bone marrow originating cells, including precursor
endothelial cells, that home into the surviving tumor
areas aiding revascularization [22]. It has been suggested
that combinations of VDA with anti-angiogenic drugs
could achieve better treatment outcomes. Indeed early
studies in animal models demonstrated that an anti-
VEGF monoclonal antibody in combination with the
OXi4503 treatment prevented mobilization of precursor
endothelial cells and resulted in significant tumor reduc-
tion [22]. Our study using the anti-angiogenic drug Su-
nitinib in combination with OXi4503 demonstrated
significant reduction in viable tumor and prolonged ani-
mal survival compared to either single drug treatment.
Fig. 4 Changes in tumor proliferation following different treatment regimens. a Formalin fixed liver sections with CRC liver metastases were stained
for the proliferation marker KI67. First column Scale bar = 200 μm. Second column represents area within the inset of the first column at a higher
magnification. Scale bar = 50 μm. b enumeration of proliferating cells *P < 0.003, combination vs OXi4503 and #P < 0.016, combination vs Sunitinib.
Data was not normally distributed and non-parametric analysis was performed and statistical significance determined using Mann-Whitney U test
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We used drug concentrations that we or others deter-
mined to be tolerated and effective in the mouse species.
In the first study Sunitinib was given 2 days before the
OXi4503 treatment in order to normalise the tumor vas-
culature for more efficient delivery of the OXi4503 [3],
however the results show the combination treatment to
be toxic to the animals. Sunitinib has already been
approved for the clinical treatment of certain types of tu-
mors and has been shown to significantly extent pa-
tients’ life expectancy in these diseases [23]. Clinical
and preclinical reports however have shown that Suniti-
nib also affects normal vessels and when used as a
monotherapy or in combination treatments for long
term or in high dosage it is often associated with ad-
verse effects including hypertension, arterial thrombo-
embolic events, renal damage, impaired wound healing,
and liver toxicity [24, 25]. El Mesbahi et al. reported hep-
atic cytolysis in two patients following Sunitinib treatment
but reduced Sunitinib dosing returned the patients liver
chemistries to normal levels [26]. Our studies also demon-
strate that liver toxicity can be ameliorated with shorter
exposure to Sunitinib and still maintain combined gain in
efficacy. Taken together these results suggest optimisation
of dose and/or length of treatment might overcome the
toxicity problem in the clinic.
We examined the likely mechanisms that contributed
to the increased efficacy of the combination treatment.
Revascularization was completely inhibited compared to
the single OXi4503 treatment. In agreement with
Czabanka et al. our study also demonstrated the ability
of Sunitinib to interfere with pre-existing tumor vessels
in addition to inhibiting new vessel formation [27].
Interestingly Sunitinib also preferentially destroys the
Fig. 6 OXi4503, Sunitinib and combination treatments induce EMT
in the surviving tumor cells. Formalin-fixed control and treated
tumor sections were stained with antibodies to E-cadherin, ZEB1,
or Vimentin. Positive expression is detected by the brown staining.
Scale bar = 50 μm. L = liver, T = live tumor. NT = necrotic tumor.
Images are representative for each treatment group (n ≥ 5 animals)
Fig. 5 Changes in tumor apoptosis following different treatment regimens. a Formalin fixed liver sections with CRC liver metastases were stained
for caspase 3 (apoptosis marker) First column Scale bar = 200 μm. Second column represents area within the inset of the first column at a higher
magnification. Scale bar = 50 μm. b enumeration of apoptotic cells. Treatment groups vs control group (*P <0.003), Combination treated group vs
OXi4503 treated (#P <0.006) and vs Sunitinib (#P <0.02. Data is expressed as mean value ± SEM, with n ≥ 5 for each group. Data was not normally
distributed and non-parametric analysis was performed and statistical significance determined using Mann-Whitney U test
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central tumor vessels thus supporting our previous find-
ing that tumor vessels in the periphery are more robust
and resistant to treatments [10]. While Sunitinib treat-
ment reduced vessel density compared to control tu-
mors it did not affect some of the larger established
tumor vessels and thus it was not as effective in redu-
cing tumor mass as the OXi4503 treatment. The add-
itional efficacy of the combination treatment is due to
inhibition of neo-angiogenesis since a significant reduc-
tion in tumor vessel density was found compared to ei-
ther treatment alone. These results are in complete
agreement with a recent study by Lee et al. [28] who
also demonstrated a significant vessel reduction upon
OXi4503/Sunitinib treatment in a subcutaneous human
xenograft. Our results in addition demonstrate these ef-
fects in an orthotopic CRLM model in an immunologic-
ally competent host. We also found significant increase in
tumor apoptosis and significant decrease in tumor prolif-
eration, in the combination treatment compared to single
arm treatments, thus accounting for the observed reduc-
tion in viable tumor. Yang et al. reported that Sunitinib in-
duces medulloblastoma tumor cell apoptosis by inhibiting
the STAT3 and AKT pathways [29]. These changes most
likely result from increased hypoxia, lack of nutrient avail-
ability and ROS accumulation.
Taken together these results indicate promise for test-
ing this combination in the clinic, however there are
concerns that suggest additional preclinical work is
needed. The first issue that arose from our study is the
observed liver toxicity associated with Sunitinib treat-
ment which was exacerbated in the combination
treatment. The second issue arising from this study and
other published studies is that while the combination
treatment increases efficacy and survival, tumor progres-
sion ultimately occurs. We used a single maximum
tolerated dose of OXi4503 in this study. In other studies
it was shown that repeated OXi4503 dosing once tumor
vessels re-establish is effective in controlling tumour
growth [21]. More recent studies however show that
new tumor vessels eventually become resistant to repeat
treatments [28]. Similarly AAs whether in single or com-
bination treatments at best prolong survival but tumor
resistance and often increased metastasis occur [30].
These findings suggest that while VDA/AA combination
treatment could prolong survival, this treatment may be
more effective if administered with additional treatment
modalities aiming to counteract the development of re-
sistance. In our previous studies we demonstrated a
widespread but transient EMT in the tumor cells within
the viable rim after OXi4503 treatment. EMT has been
shown to be associated with metastasis, and stem cell at-
tributes including tumour resistance to drugs and other
therapies [31]. In this study we also demonstrated EMT
cell morphology in the Sunitinib and the combination
treatments. Interestingly E-cadherin expression while
lower than the control did not completely disappear as
observed in our previous OXi4503 study but it re-
distributed from the cell junctions to the cytoplasm and
nucleus, while ZEB1 and Vimentin expression were both
high at the termination of the treatment. Nuclear accu-
mulation of E-cadherin has been reported in several
types of cancers; oesophageal squamous cell carcinomas,
Fig. 7 OXi4503/Sunitinib combination treatment prolongs survival of mice with CRC liver metastasis. Kaplan–Meier analysis for cancer related
survival between control, OXi4503, Sunitinib and Sunitinib/OXi4503 treated groups. Data is expressed as mean value ± SEM, with n = 10 for each
group. Sunitinib (40 mg/kg)/OXi4503 (100 mg/kg) combination treatment resulted in significant improvement in median or overall survival
compared to control as found by log rank test (Sunitinib/OXi4503 vs Control P < 0.004, vs OXi4503 P < 0.006, vs Sunitinib P < 0.005)
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pituitary adenomas and less frequently in colon cancers
(6 %) [32, 33] and has been associated with tumor invasion.
These results suggest that EMT is a dynamic process
responding to changes in the microenvironment. Thus a
very acute treatment such as a single OXi4503 treatment,
results in immediate loss of E-cadherin and a significant
but transient up-regulation of ZEB1 while Vimentin has a
longer turnover time [9]. Continuous Sunitinib treatment
on the other hand is a less acute treatment and E-cadherin
becomes redistributed rather than totally lost, while ZEB1
and Vimentin expression remain high for the duration of
the treatment. Nevertheless the surviving tumor cells in
both continuous Sunitinib and the combination treatments
display EMT morphology that could contribute to therapy
resistance and the increased incidence of metastasis associ-
ated with Sunitinib treatment [30]. Targeting the mesen-
chymal tumor cells or preventing the EMT transition in
combination to VDA/AA treatment could produce a lon-
ger lasting treatment or a total therapy.
Conclusion
In conclusion, our results demonstrate the potential of
VDAs and AAs in combination therapy to treat CRCLM.
However, the study also highlights the challenges which
need to be addressed before these therapies can be safely
and efficiently introduced into the clinic. Careful dose/
time regimen needs to be explored for maximal benefit
with least adverse effects. Further a treatment regimen
consisting of just VDAs and AAs may result in initial
regression of the tumor, however surviving tumor cells
appear to undergo EMT, making them resistant to treat-
ment and more likely to metastasize to a distant site.
These results suggest that VDAs and AAs may exert
maximal effects when combined with EMT inhibitors.
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Additional file 1: Effects of treatment on tumor. Tumor death is
evaluated with H&E staining. Live tumor areas are enclosed within
double lines. A single OXi4503 treatment has an immediate effect on
tumor death reaching a maximum at 24 h. By day five there is regrowth
of the tumor into the necrotic centre. Continous Sunitinib treatment has
a gradual reducing effect on live tumor but it does not reach the levels
of tumour killing seen by the OXi4503 treatment at 24 h. (PDF 381 kb)
Additional file 2: OXi4503, Sunitinib and combination treatments
induce EMT in the surviving tumor cells. Formalin-fixed control and
treated tumor sections were stained with antibodies to E-cadherin, ZEB1,
or Vimentin. Positive expression is detected by the brown staining. Scale
bar = 200 mm. L = liver, T = live tumor. NT = necrotic tumor. Images are
representative for each treatment group (n ≥ 5 animals). (PDF 417 kb)
Additional file 3: Intensity score of EMT changes in tumor metastases
following 5 days of OXi4503, Sunitinib and combination treatments.
E-cadherin expression decreased in all treatment groups but only
reached significance in the OXi4503 treatment (*P = 0.005). ZEB1 expression
significantly increased in the Sunitinib and Sunitinib/OXi4503 combination
treatments (*P < 0.025). Vimentin expression revealed a significant increase
following OXi4503 treatment (*P = 0.037). (PDF 249 kb)
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